Advertisement

Osteoporosis International

, Volume 24, Issue 9, pp 2509–2517 | Cite as

Primary non-adherence to bisphosphonates in an integrated healthcare setting

  • K. ReynoldsEmail author
  • P. Muntner
  • T. C. Cheetham
  • T. N. Harrison
  • D. E. Morisky
  • S. Silverman
  • D. T. Gold
  • S. S. Vansomphone
  • R. Wei
  • C. D. O’Malley
Original Article

Abstract

Summary

We estimated primary non-adherence to oral bisphosphonate medication and examined the factors associated with primary non-adherence. Nearly 30 % of women did not pick up their new bisphosphonate within 60 days. Identifying barriers and developing interventions that address patients’ needs and concerns at the time a new medication is prescribed are warranted.

Introduction

To estimate primary non-adherence to oral bisphosphonate medications using electronic medical record data in a large, integrated healthcare delivery system and to describe patient and prescribing provider factors associated with primary non-adherence.

Methods

Women aged 55 years and older enrolled in Kaiser Permanente Southern California (KPSC) with a new prescription for oral bisphosphonates between December 1, 2009 and March 31, 2011 were identified. Primary non-adherence was defined as failure to pick up the new prescription within 60 days of the order date. Multivariable logistic regression models were used to investigate patient factors (demographics, healthcare utilization, and health conditions) and prescribing provider characteristics (demographics, years in practice, and specialty) associated with primary non-adherence.

Results

We identified 8,454 eligible women with a new bisphosphonate order. Among these women, 2,497 (29.5 %) did not pick up their bisphosphonate prescription within 60 days of the order date. In multivariable analyses, older age and emergency department utilization were associated with increased odds of primary non-adherence while prescription medication use and hospitalizations were associated with lower odds of primary non-adherence. Prescribing providers practicing 10 or more years had lower odds of primary non-adherent patients compared with providers practicing less than 10 years. Internal medicine and rheumatology providers had lower odds of primary non-adherent patients than primary care providers.

Conclusion

This study found that nearly one in three women failed to pick up their new bisphosphonate prescription within 60 days. Identifying barriers and developing interventions aimed at reducing the number of primary non-adherent patients to bisphosphonate prescriptions are warranted.

Keywords

Adherence Bisphosphonates Postmenopausal osteoporosis Primary non-adherence 

Notes

Acknowledgements

This study was funded by a contractual agreement between Kaiser Permanente Southern California and Amgen Inc., Thousand Oaks, CA.

Conflicts of interest

Dr. O’Malley is an employee of Amgen Inc. and owns stock in Amgen Inc. Drs. Muntner, Gold, Silverman, and Morisky have served as advisors for Amgen Inc. Drs. Muntner, Gold and Silverman have served as consultants for Amgen Inc. Drs. Reynolds and Muntner received research support from Amgen Inc. Dr. Silverman has served as an advisor for Lilly, Novartis and Pfizer/Wyeth. Dr. Silverman has served as a consultant for Genentech, Lilly, Novartis and Pfizer/Wyeth. Dr. Silverman has received research support from Lilly and Pfizer/Wyeth. This study was funded by a contractual agreement between Kaiser Permanente Southern California and Amgen Inc., Thousand Oaks, CA.

References

  1. 1.
    Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM (1993) Primary non-compliance with prescribed medication in primary care. Bmj 307:846–848PubMedCrossRefGoogle Scholar
  2. 2.
    Gadkari AS, McHorney CA (2010) Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin 26:683–705. doi: 10.1185/03007990903550586 PubMedCrossRefGoogle Scholar
  3. 3.
    Waalen J, Bruning AL, Peters MJ, Blau EM (2009) A telephone-based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. Am J Manag Care 15:e60–70PubMedGoogle Scholar
  4. 4.
    Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456. doi: 10.1177/1062860607307990 PubMedCrossRefGoogle Scholar
  5. 5.
    Greenwald B, Bardwell A, Malinak J, Rude R, Silverman SL, White-Greenwald M (2002) New bone density report format influences patient compliance in filling prescriptions for osteoporosis. Clin J Wom Health 2:13–18CrossRefGoogle Scholar
  6. 6.
    Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44:1640–1661. doi: 10.1111/j.1475-6773.2009.00989.x PubMedCrossRefGoogle Scholar
  7. 7.
    Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, Chen W, Jacobsen SJ (2012) Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. The Permanente Journal 16:37–41PubMedGoogle Scholar
  8. 8.
    Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619PubMedCrossRefGoogle Scholar
  9. 9.
    Hosmer DW, Lemeshow S (1989) Applied logistic regression. John Wiley & Sons, New YorkGoogle Scholar
  10. 10.
    Shin J, McCombs JS, Sanchez RJ, Udall M, Deminski MC, Cheetham TC (2012) Primary nonadherence to medications in an integrated healthcare setting. Am J Manag Care 18:426–434PubMedGoogle Scholar
  11. 11.
    Fischer MA, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Hutchins D, Liberman JN, Brennan TA, Shrank WH (2011) Trouble getting started: predictors of primary medication nonadherence. Am J Med 124(1081):1089–1022. doi: 10.1016/j.amjmed.2011.05.028 Google Scholar
  12. 12.
    Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, Shetterly S, Xu S, Steiner JF (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27:57–64. doi: 10.1007/s11606-011-1829-z PubMedCrossRefGoogle Scholar
  13. 13.
    Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL (2009) Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 122(961):967–913. doi: 10.1016/j.amjmed.2008.12.021 Google Scholar
  14. 14.
    Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF (2009) Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med 24:233–237. doi: 10.1007/s11606-008-0870-z PubMedCrossRefGoogle Scholar
  15. 15.
    Liberman JN, Hutchins DS, Popiel RG, Patel MH, Jan SA, Berger JE (2010) Determinants of primary nonadherence in asthama-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits 2:111–118Google Scholar
  16. 16.
    Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane database of systematic reviews CD000011. doi: 10.1002/14651858.CD000011.pub3
  17. 17.
    Derose SF, Green K, Marrett E, Cheetham TC, Chiu VY, Harrison TN, Reynolds K, Vansomphone SS, Scott RD (2012) Automated outreach to increase primary adherence to cholesterol-lowering medications. Arch Intern Med Published online: doi: 10.1001/2013.jamainternmed.717
  18. 18.
    Gerend MA, Erchull MJ, Aiken LS, Maner JK (2006) Reasons and risk: factors underlying women's perceptions of susceptibility to osteoporosis. Maturitas 55:227–237. doi: 10.1016/j.maturitas.2006.03.003 PubMedCrossRefGoogle Scholar
  19. 19.
    Hsieh C, Novielli KD, Diamond JJ, Cheruva D (2001) Health beliefs and attitudes toward the prevention of osteoporosis in older women. Menopause 8:372–376PubMedCrossRefGoogle Scholar
  20. 20.
    McHorney CA, Spain CV (2011) Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008. Health Expect 14:307–320. doi: 10.1111/j.1369-7625.2010.00619.x PubMedCrossRefGoogle Scholar
  21. 21.
    Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415–423PubMedCrossRefGoogle Scholar
  22. 22.
    Scoville EA, de Leon P, Lovaton P, Shah ND, Pencille LJ, Montori VM (2011) Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One 6:e18468. doi: 10.1371/journal.pone.0018468 PubMedCrossRefGoogle Scholar
  23. 23.
    Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23:1815–1821. doi: 10.1007/s11606-008-0772-0 PubMedCrossRefGoogle Scholar
  24. 24.
    Danese MD, Badamgarav E, Bauer DC (2009) Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 24:1819–1826. doi: 10.1359/jbmr.090506 PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

Authors and Affiliations

  • K. Reynolds
    • 1
    Email author
  • P. Muntner
    • 2
  • T. C. Cheetham
    • 3
  • T. N. Harrison
    • 1
  • D. E. Morisky
    • 4
  • S. Silverman
    • 5
  • D. T. Gold
    • 6
  • S. S. Vansomphone
    • 7
  • R. Wei
    • 1
  • C. D. O’Malley
    • 8
  1. 1.Department of Research and EvaluationKaiser Permanente Southern CaliforniaPasadenaUSA
  2. 2.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Pharmacy Analytical ServiceKaiser PermanenteDowneyUSA
  4. 4.Department of Community Health SciencesUCLA Fielding School of Public HealthLos AngelesUSA
  5. 5.Department of Medicine, Rheumatology DivisionCedars-Sinai/UCLALos AngelesUSA
  6. 6.Departments of Psychiatry & Behavioral Sciences, Sociology, and Psychology & NeuroscienceDuke University Medical CenterDurhamUSA
  7. 7.Pharmacy Analytical ServiceKaiser PermanenteDowneyUSA
  8. 8.Center for Observational Research, Amgen Inc.South San FranciscoUSA

Personalised recommendations